Ventus Therapeutics Nominates Potential First|in|Class cGAS ...

Ventus retains the right to develop chemically distinct systemic NLRP3 inhibitors for specific inflammatory and respiratory diseases. We are in lead ...

Ventus Therapeutics - Recent News & Activity - Crunchbase

Business Wire — Ventus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively ... ... cGAS, taking ...

News feed | La French Tech ecosystem map

Ventus Therapeutics Nominates Potential First-In-Class Cgas Inhibitor Vent-03 As Inaugural Development Candidate In Cgas Franchise. WALTHAM, Mass. MONTREAL ...

Chilblain Lupus 1 - Drugs, Targets, Patents - Synapse

Ventus Therapeutics Nominates Potential First-in-Class cGAS Inhibitor VENT-03 as Inaugural Development Candidate in cGAS Franchise. The nomination of VENT-03 ...

Ventus Therapeutics Named to C&E News 10 Start-Ups to Watch ...

Ventus was selected by C&E News based on the company's proprietary Structural Immunology platform, which enables the pursuit of previously ...

Ventus Therapeutics - Recent News & Activity - Crunchbase

Business Wire — Ventus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively ... ... cGAS, taking option ...

Ventus Therapeutics Inc. - [LSS] Life-Sciences-Scandinavia.com

Ventus Therapeutics Inc. ; Period, Start, 2020-05-06 emerged ; Product, Industry, drug discovery ; Region, Waltham, MA ; Country, United States (USA).

Overview - Ventus Therapeutics

Ventus develops differentiated therapies at a fast pace. We screened our first target in 2020 and nominated three development candidates in 2022: VENT-03, a ...

Ventus Therapeutics Inc., Montréal - [LSUS] Life-Sciences-USA.com

[3] Ventus Therapeutics, Inc.. (3/31/22). "Press Release: Ventus Therapeutics Appoints Christine Ha as Chief Financial Officer". Waltham, MA & Montréal, QC ...

Introducing Fierce Biotech's 2023 Fierce 15

What makes Fog Fierce: Going into 2023, FogPharma's future appeared anything but cloudy. The company had raised a $178 million series D round in ...

Ventus Therapeutics | Drug Developments | Pipeline Prospector

Not Applicable. Deal Type : Not Applicable. DEALS_DEV arrow-down · Ventus Therapeutics Nominates Potential First-in-Class cGAS Inhibitor VENT-03 as Inaugural ...

2024 Medicinal Chemistry Conference GRC

GRC Connects 2.0 matches a long-time attendee at a Gordon Research Conference with a first ... Stéphane Ciblat (Ventus Therapeutics, Canada). "Drug Discovery ...

Ventus Therapeutics to Present at 2023 Bloom Burton & Co ...

[2] Ventus Therapeutics, Inc.. (3/31/22). "Press Release: Ventus Therapeutics Appoints Christine Ha as Chief Financial Officer". Waltham, MA & Montréal, QC ...

Ventus Therapeutics Appoints Victor Lobanov, PhD, as Head of ...

Our lead programs target key innate immune modulators, including NLRP3 and cGAS. For more information, please visit www.ventustx.com and engage ...

Gold Leaf Awards - BIOTECanada

Ventus Therapeutics is a clinical-stage biopharmaceutical company deploying deep protein science expertise and a proprietary computational chemistry platform to ...

C&EN's 2020 10 Start-Ups to Watch - American Chemical Society

Ventus Therapeutics is designing small-molecule drug candidates that target proteins of the innate immune system, including NLRP3. When ...

C&EN 10 Companies to Watch 2020 - Ventus Therapeutics

... cGAS-STING ... its breadth of targets and potential disease areas but also in how it discovered its drug candidates in the first place.

ImmuneSensor Therapeutics Appoints Veteran Biopharma

Chen as we expand and advance the company's proprietary small molecule pipeline of novel cGAS inhibitors in inflammatory conditions as well as ...

Ventus Therapeutics launches to drug inflammasomes, cGAS, and ...

Ventus CEO Marcelo Bigal, who joined the company in May 2019, says Ventus will first focus on three undisclosed targets, with the ability to ...

Collectibles and Antiques News